133 related articles for article (PubMed ID: 31500432)
21. Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases.
Shindoh J
Chin Clin Oncol; 2019 Oct; 8(5):47. PubMed ID: 31500425
[TBL] [Abstract][Full Text] [Related]
22. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.
Schirripa M; Bergamo F; Cremolini C; Casagrande M; Lonardi S; Aprile G; Yang D; Marmorino F; Pasquini G; Sensi E; Lupi C; De Maglio G; Borrelli N; Pizzolitto S; Fasola G; Bertorelle R; Rugge M; Fontanini G; Zagonel V; Loupakis F; Falcone A
Br J Cancer; 2015 Jun; 112(12):1921-8. PubMed ID: 25942399
[TBL] [Abstract][Full Text] [Related]
23. [I. Impact of Surgical Margin Status on Outcomes of Surgical Resection for Colorectal Liver Metastases].
Hosokawa I; Adam R; Miyazaki M; Shimizu H; Koda K; Ohtsuka M
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1417-1422. PubMed ID: 30382036
[No Abstract] [Full Text] [Related]
24. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
25. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13.
Kawamata H; Yamashita K; Kojo K; Ushiku H; Ooki A; Watanabe M
Genomics; 2015 Aug; 106(2):71-5. PubMed ID: 26026309
[TBL] [Abstract][Full Text] [Related]
26. Impact of timing and cycles of systemic chemotherapy on survival outcome of colorectal liver metastases patients treated by percutaneous microwave ablation.
Zhang K; Yu J; Zhou F; Yu X; Li X; Wang J; Han Z; Cheng Z; Liang P
Int J Hyperthermia; 2016 Aug; 32(5):531-8. PubMed ID: 27121037
[TBL] [Abstract][Full Text] [Related]
27. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
[TBL] [Abstract][Full Text] [Related]
28. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection.
Kokudo N; Miki Y; Sugai S; Yanagisawa A; Kato Y; Sakamoto Y; Yamamoto J; Yamaguchi T; Muto T; Makuuchi M
Arch Surg; 2002 Jul; 137(7):833-40. PubMed ID: 12093342
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.
O Connor JM; Sanchez Loria F; Ardiles V; Grondona J; Sanchez P; Andriani O; Fauda M; Brancato F; Huertas E; Alvarez F; de Santibañes E
Future Oncol; 2019 Sep; 15(27):3149-3157. PubMed ID: 31426677
[No Abstract] [Full Text] [Related]
30. Local treatment of oligometastatic disease: current role.
Winkelmann MT; Clasen S; Pereira PL; Hoffmann R
Br J Radiol; 2019 Aug; 92(1100):20180835. PubMed ID: 31124700
[TBL] [Abstract][Full Text] [Related]
31. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
32. Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control.
Shady W; Petre EN; Do KG; Gonen M; Yarmohammadi H; Brown KT; Kemeny NE; D'Angelica M; Kingham PT; Solomon SB; Sofocleous CT
J Vasc Interv Radiol; 2018 Feb; 29(2):268-275.e1. PubMed ID: 29203394
[TBL] [Abstract][Full Text] [Related]
33. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
[TBL] [Abstract][Full Text] [Related]
34. Limitations of molecular biomarkers in patients with resectable colorectal liver metastases.
Brudvik KW; Shindoh J
Chin Clin Oncol; 2019 Oct; 8(5):48. PubMed ID: 31500431
[TBL] [Abstract][Full Text] [Related]
35. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
36. The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation.
Jiang BB; Yan K; Zhang ZY; Yang W; Wu W; Yin SS; Chen MH
Int J Hyperthermia; 2019 Jan; 36(1):211-219. PubMed ID: 30663903
[TBL] [Abstract][Full Text] [Related]
37. ASO Author Reflections: Can We Predict an Unsalvageable Recurrence Following Colorectal Liver Metastasectomy?
Okuno M; Conrad C
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):549-550. PubMed ID: 30565037
[No Abstract] [Full Text] [Related]
38. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
39. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
40. Double
Deshwar A; Margonis GA; Andreatos N; Barbon C; Wang J; Buettner S; Wagner D; Sasaki K; Beer A; Løes IM; Pikoulis E; Damaskos C; Garmpis N; Kamphues K; He J; Kaczirek K; Poultsides G; Lønning PE; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Anticancer Res; 2018 May; 38(5):2891-2895. PubMed ID: 29715113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
